Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of Adalimumab Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive Spondyloarthritis
NCT03561649Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of adalimumab in spondyloarthritis (SpA), sponsored by CHU Grenoble Alpes. Primary endpoint: Ankylosing Spondylitis Disease Activity Score at 6 months. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT03561649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561649.